Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128162 · ClinicalTrials.gov registry record · Phase 2
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
A Phase 2 study, sponsored by Kevin Boehnke.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT05128162 is a Phase 2 study that has completed, run by Kevin Boehnke. The registered enrollment target is 17 participants.
The verdict
NCT05128162, a Phase 2 study, has completed, sponsored by Kevin Boehnke.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating psilocybin therapy as a treatment for FM. The primary objective of this study is to evaluate the clinical benefit of oral psilocybin in concert with psychotherapy to treat chronic pain symptoms in patients with FM.
Interventions
- BEHAVIORAL Psychotherapy
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2024-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05128162
The ClinicalTrials.gov registry entry for NCT05128162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kevin Boehnke, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psychotherapy is the first listed.
NCT05128162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05128162 about?
NCT05128162 is a clinical study titled "Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia". The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating psilocybin therapy as a treatment for FM. The primary objective of this study is to evaluate the clinical ...
What is the current status of trial NCT05128162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2023-09-27. Estimated completion is 2024-06-12.
What interventions are being tested in trial NCT05128162?
The interventions under investigation include: Psychotherapy (BEHAVIORAL), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05128162?
This trial is sponsored by Kevin Boehnke, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.